Table 2

Univariable and multivariable Cox regression analyses of potential predictors for 5-year explantation risks due to diminished pain relief; 395 patients (five Saluda patients excluded)

VariableUnivariable analysisMultivariable analysis
HR95% CIP valueHR95% CIP value
Age (years)1.000.98 to 1.030.801.000.97 to 1.030.99
Gender
 Male1*1
 Female1.070.59 to 1.960.821.210.64 to 2.260.56
Indication
 PSPS211
 Other0.810.44 to 1.520.520.640.31 to 1.350.24
Diabetes
 No11
 Yes1.500.53 to 4.170.451.740.58 to 5.230.32
Immunosuppressive treatment
 No11
 Yes2.410.58 to 9.960.232.460.57 to 10.650.23
Company
 Boston Scientific11
 Nevro0.980.38 to 2.530.970.810.30 to 2.170.68
 Medtronic1.960.93 to 4.110.082.721.18 to 6.300.02
 Abbott1.790.70 to 4.60.231.560.31 to 7.830.59
Rechargeable
 No11
 Yes0.910.49 to 1.670.762.210.97 to 5.070.06
DRG stimulation
 No11
 Yes3.031.20 to 7.710.026.731.26 to 35.880.03
  • *Reference category. Significant numbers are in bold.

  • DRG, dorsal root ganglion; PSPS2, persistent spinal pain syndrome type 2.